NCT06305754 trial: what clinicians have said so far
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- NCT06305754 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT06305754 (sacituzumab tirumotecan in EGFR-mutated advanced nonsquamous non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06305754 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan; Pemetrexed; Carboplatin; H1 Receptor Antagonist; H2 Receptor Antagonist; Acetaminophen (or equivalent); Dexamethasone (or equivalent); Steroid Mouthwash (dexamethasone or equivalent)
- Arms
- Sacituzumab tirumotecan · Experimental
- Pemetrexed Plus Carboplatin · Active comparator
- Enrollment
- 550 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jun 11, 2024
- Primary completion
- Aug 17, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06305754 · updated Oct 30, 2026